V8 Peptides — Engineered Performance
Research Library
Selank in Animal Models: Preclinical Findings Reviewed
SelankPreclinical

Selank in Animal Models: Preclinical Findings Reviewed

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What do preclinical studies report about Selank? Selank, the synthetic heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro, has been studied mostly by one research network in rats and mice. Reported findings include altered expression of 45 neurotransmission genes in rat frontal cortex one hour after a single administration, a reduction in a composite morphine-withdrawal score in rats, and changes in inflammation-related gene expression in mouse spleen. The work uses single-dose, short-timecourse designs, is largely transcript-level, and has seen limited independent replication, so it is best read as hypothesis-generating. Selank is supplied for laboratory research use only.

Selank is a synthetic analog of the endogenous peptide tuftsin, and the V8 Selank page describes it as studied for anxiolytic and immunomodulatory signaling in research models, with research areas in GABAergic signaling, anxiolytic behavior models and immunomodulation studies. This article does something narrower than the Selank research overview or the existing mechanism article: it goes through individual published animal and tissue studies one at a time, says what each measured, and says what it cannot show. It is a reading guide to the primary literature, for laboratory research use only, and it makes no statement about use in people.

The material: what Selank is on paper

The V8 listing gives the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, the molecular formula C33H57N11O9, a 10 mg lyophilized presentation, and ≥98% purity by HPLC. A review of Selank's molecular biology describes the heptapeptide as showing prolonged anti-anxiety and nootropic effects in the authors' hands and presents radioligand-binding work on its interaction with the GABA system (Vyunova et al., 2018). The sequence combines the tuftsin tetrapeptide Thr-Lys-Pro-Arg with a Pro-Gly-Pro tail, an architecture covered in what is Selank. The calculated average mass from the stated formula is about 752 Da, which is the value to compare against an observed mass on a certificate.

Most of the primary literature on Selank comes from one network of Russian laboratories, with a recurring set of authors. That is not a criticism of the work, but it matters for how much weight a reader should put on convergence: many of the findings below are from the same lab group using related designs, so they are not independent confirmations.

Study 1: expression of neurotransmission genes in rat frontal cortex

The study with the broadest scope examined the expression of 84 genes involved in neurotransmission, including GABA receptor subunits, transporters, ion channels and dopamine and serotonin receptors, in the frontal cortex of rats 1 and 3 hours after administration of Selank or GABA at 300 µg/kg, using real-time PCR (Volkova et al., 2016). The authors reported significant changes in 45 genes at 1 hour and 22 genes at 3 hours, and a positive correlation between the changes caused by Selank and those caused by GABA at the 1-hour time point. They concluded that one possible molecular mechanism is allosteric modulation of the GABAergic system. The introduction of the paper notes clinical observations of similarity between Selank and benzodiazepines; the study itself is a transcript panel in rats.

What this supports: Selank administration was followed by broad shifts in mRNA levels in this tissue at these times. What it does not show: that the transcript changes translate into protein or functional changes, that they would persist, or that they cause any behavioral effect. The abstract describes no benzodiazepine comparator, so statements about similarity to benzodiazepines rest on the correlation with GABA and on other work.

Study 2: radioligand binding and the allosteric hypothesis

The molecular follow-up used radioligand-receptor methods on isolated brain-cell plasma membranes. It reported that Selank affected [3H]GABA binding as a positive allosteric modulator, that the joint action of Selank and some benzodiazepines was not simply additive, and that Selank could block the modulatory activity of diazepam and olanzapine in this assay; the authors suggested the binding sites of the peptide and these compounds are different but may partly overlap (Vyunova et al., 2018). This is an in vitro membrane-binding result. It is the main support for the allosteric idea, and it is a hypothesis that requires structural or electrophysiological confirmation, which the abstract does not describe.

Study 3: a rat model of morphine withdrawal

The most behavioral of the studies in this set used outbred rats in a naloxone-precipitated morphine withdrawal model. A single intraperitoneal administration of Selank at 0.3 mg/kg, described by the authors as an anxiolytic dose, was reported to reduce the total index of morphine withdrawal syndrome by 39.6%, to attenuate convulsive reactions, ptosis and posture disorders, and to raise the tactile sensitivity threshold nine-fold relative to the active control group; diazepam at 2 mg/kg reduced the index by 49.3% and raised the threshold thirteen-fold, so Selank was slightly inferior to diazepam in pharmacological activity (Konstantinopolsky et al., 2022). The authors concluded that Selank, like diazepam, weakens the aversive signs of morphine withdrawal in rats with opiate dependence.

Two features of this design are worth noting for a reader. It has a positive comparator, which many Selank papers lack, and it reports effect sizes. It is also a single-dose, acute-readout study in one species, and the withdrawal index is a composite of observer-scored signs, so blinding and scoring procedures, which the abstract does not describe, are the details to check in the full paper.

Study 4: inflammation-related genes in mouse spleen

A separate thread looks at immune-related transcripts. One study examined 84 inflammation-related genes (chemokines, cytokines and receptors) in mouse spleen 6 and 24 hours after a single intraperitoneal administration of Selank at 100 µg/kg, and also tested two Selank fragments. It reported significant changes in 34 genes, with the Bcl6 gene altered by each of the peptides and changes in Bcl6 target and corepressor genes (Kolomin et al., 2011). A follow-up studied the time course of four genes, C3, Casp1, Il2rg and Xcr1, after Selank or the dipeptide Gly-Pro. It reported a three-fold decrease in C3 mRNA 30 minutes after Selank, similar changes with Gly-Pro, a wave-like pattern in Casp1, and early changes in Il2rg and Xcr1, and concluded that the dipeptide may contribute to the effect of the parent peptide (Kolomin et al., 2014).

The Gly-Pro result matters chemically: it suggests that some activity attributed to Selank may come from a breakdown fragment, which complicates interpretation of any experiment in which the intact peptide is not verified by analysis over time.

Study 5: enkephalin degradation and BDNF

Two further titles belong in the map, though the details here are limited to what the titles state. A paper on tritium-labeled Leu-enkephalin examined the inhibiting effect of Selank on enkephalin degradation (Zolotarev et al., 2004), which is the basis of the proposed enkephalinase mechanism. A second paper reported that intranasal administration of Selank regulates BDNF expression in the rat hippocampus in vivo (Inozemtseva et al., 2008). Neither abstract was available for a line-by-line reading at the time of writing, so no quantitative detail is given; a reader should consult the full texts.

StudySystemReadoutMain reported resultKey limit
Volkova et al., 2016Rat frontal cortex, 300 µg/kg84-gene qPCR panel at 1 and 3 h45 genes changed at 1 h; 22 at 3 hTranscript-level; no behavior
Vyunova et al., 2018Isolated brain membranes[3H]GABA bindingPositive allosteric modulation reportedIn vitro; no structural proof
Konstantinopolsky et al., 2022Rat morphine withdrawal, 0.3 mg/kgComposite withdrawal indexIndex reduced 39.6%; diazepam 49.3%Single dose; observer-scored
Kolomin et al., 2011Mouse spleen, 100 µg/kg84 inflammation genes at 6 and 24 h34 genes changed; Bcl6 alteredTranscript-level; one tissue
Kolomin et al., 2014Mouse spleen, 100 µg/kgFour genes, short time courseC3 down about 3-fold at 30 min; Gly-Pro similarFour genes only

What the set of studies can and cannot support

Read together, the studies support a narrow statement: in these rodent and membrane systems, Selank was followed by measurable changes in neurotransmission and immune-related transcripts, by an in vitro allosteric effect on GABA binding, and by a reduced withdrawal score in one rat model. They do not establish the pharmacokinetics of intact Selank in brain tissue, since the abstracts do not report it; nor do they establish durability, dose-response across a range, or independent replication. The administered amounts in the abstracts are 100 to 300 µg/kg and 0.3 mg/kg, in different species and routes, and are quoted only as what each study reported, not as a recommendation for any experiment.

QuestionSupported by the abstracts?Comment
Selank changes gene expression after one administration in rodentsYesCortex and spleen; hours-scale
It modulates GABA binding in vitroReportedMembrane assay; mechanism not structurally proven
It reduces a withdrawal index in ratsReportedSingle dose; composite score
Its effects require the intact peptideUnclearGly-Pro reproduced part of the spleen response
Independent replicationNot describedSame network authored most studies

A neutral reading is that the literature points to the GABAergic and immune transcriptional systems as places to look, and that independent labs with defined controls would add the most. That also applies to the related comparison of Selank with its sister peptide in Selank vs Semax.

Design lessons for a laboratory

  • Verify the peptide. Confirm identity by mass (about 752 Da from C33H57N11O9) and purity by HPLC before use; see Selank purity testing and how to read a COA.
  • Plan for the fragment problem. Because Gly-Pro reproduced part of the transcript response, consider including the dipeptide as a control arm.
  • Use time courses. The reported effects are time-dependent over minutes to hours; a single time point can miss or misrepresent them.
  • Add a comparator. Where the question is about GABAergic similarity, a benzodiazepine arm is more informative than vehicle alone.
  • Measure beyond mRNA. Pair transcript data with protein or functional readouts.
  • Report the vehicle and handling. Reconstitution and storage details affect a peptide; see how to reconstitute a lyophilized peptide and the calculator for the concentration arithmetic, which is mass divided by molar mass divided by volume.

Storage on the product page is refrigeration at 2–8 °C, −20 °C for long-term, with protection from heat, moisture and light. Sourcing documentation is covered in where to buy Selank and the COA library; the full catalog is in the shop.

Frequently asked questions

What is Selank?

A synthetic heptapeptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, designed as an analog of the endogenous peptide tuftsin. The V8 listing gives the formula C33H57N11O9.

What did the rat cortex gene-expression study find?

After a single administration of Selank or GABA at 300 µg/kg, 45 of 84 neurotransmission genes changed expression at 1 hour and 22 at 3 hours, with a positive correlation between the two compounds' changes at 1 hour (Volkova et al., 2016).

Is Selank an allosteric modulator of GABA binding?

One radioligand-binding study reported that it acts as a positive allosteric modulator of [3H]GABA binding in isolated brain membranes (Vyunova et al., 2018). It is an in vitro result and a hypothesis for further testing.

What was found in the morphine withdrawal model?

A single 0.3 mg/kg intraperitoneal dose reduced a composite withdrawal index by 39.6% in rats, versus 49.3% for diazepam at 2 mg/kg (Konstantinopolsky et al., 2022).

Does Selank affect immune-related genes?

In mouse spleen, 34 of 84 inflammation-related genes changed after a single 100 µg/kg administration, including Bcl6 (Kolomin et al., 2011). The effect was transcriptional, and a Gly-Pro fragment reproduced some of it.

Why does the Gly-Pro result matter?

It suggests a breakdown fragment may account for part of the response, so experiments that do not track the intact peptide are harder to interpret.

Have these findings been replicated independently?

Most come from one research network. The abstracts do not describe independent replication, so the findings should be regarded as hypothesis-generating.

Do these studies show effects in people?

No. They are rodent and in vitro studies, and this article makes no claim about use in people.

How is Selank identified analytically?

By observed mass against the roughly 752 Da calculated from the formula, and by HPLC retention and purity against a reference.

Where are storage conditions listed?

On the product page: refrigerate at 2–8 °C, −20 °C for long-term, and protect from heat, moisture and light.

Research-use statement

All material discussed here is supplied for laboratory research use only; not for human consumption, and not a drug, food or cosmetic.

Related reading: Selank Quality Control: Purity and Identity Checks, Selank Anxiolytic Peptide Research: Models and Readouts, Selank Nasal Spray Research: Intranasal Studies Explained.

References

  1. Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front. Pharmacol.. 2016;7. doi:10.3389/fphar.2016.00031
  2. Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. PPL. 2018;25(10):914-923. doi:10.2174/0929866525666180925144642
  3. Konstantinopolsky MA, Chernyakova IV, Kolik LG. Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats. Bull Exp Biol Med. 2022;173(6):730-733. doi:10.1007/s10517-022-05624-x
  4. Kolomin T, Shadrina M, Andreeva L, Slominsky P, Limborska S, Myasoedov N. Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank. Regulatory Peptides. 2011;170(1-3):18-23. doi:10.1016/j.regpep.2011.05.001
  5. Kolomin T, Morozova M, Volkova A, Shadrina M, Andreeva L, Slominsky P, et al. The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action. Molecular Immunology. 2014;58(1):50-55. doi:10.1016/j.molimm.2013.11.002
  6. Zolotarev YA, Sokolov OY, Kost NV, Vaskovsky BV, Myasoedov NF, Zozulya AA. Leu-Enkephalin Generally Labeled with Tritium in Studying the Selank Inhibiting Effect on the Enkephalin-Degrading Enzymes of Human Blood Plasma. Russian Journal of Bioorganic Chemistry. 2004;30(3):207-212. doi:10.1023/b:rubi.0000030126.09208.c3
  7. Inozemtseva LS, Karpenko EA, Dolotov OV, Levitskaya NG, Kamensky AA, Andreeva LA, et al. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci. 2008;421(1):241-243. doi:10.1134/s0012496608040066

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.